US Patent Issued to Novartis on Sept. 8 for "Compounds and compositions as Sppl2a inhibitors" (Swiss, American Inventors)

ALEXANDRIA, Va., Sept. 8 -- United States Patent no. 12,729,202, issued on Sept. 8, was assigned to Novartis AG (Basel, Switzerland).

"Compounds and compositions as Sppl2a inhibitors" was invented by Trixi Brandl (Basel, Switzerland), Claus Ehrhardt (Basel, Switzerland), Robert Epple (Solana Beach, Calif.), Christian Markert (Basel, Switzerland), Pascal Rigollier (Basel, Switzerland) and Juraj Velcicky (Basel, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to tricyclic compounds comprising a diazepinone moiety which are effective in inhibiting Sppl2a (signal peptide peptidase like protease 2a), to pharmaceutical compositions containing such inhibitors, and to methods...